BMRA - Biomerica, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Biomerica, Inc.

17571 Von Karman Avenue
Irvine, CA 92614
United States
949-645-2111
http://www.biomerica.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Mr. Zackary S. IraniChairman & CEO136.61kN/A1966
Ms. Janet MooreCFO, Treasurer, Sec. & Director113.61kN/A1951
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Corporate Governance

Biomerica, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.